Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Armando AbergelAsselah TarikArianne MallatBrigitte ChanteranneFrederic FaureDominique LarreyJerome GournayVeronique Loustaud-RattiVincent Di MartinoIsabelle Fouchard-HubertStanislas PolFrancois BaillyDidier SamuelAlbert TranMarie DodelNicolas AndantGeraldine LamblinLeon MutiMaud ReymondCamille TeilhetBruno PereiraBenjamin BuchardPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
Naïve patients with genotype 1b and non-severe fibrosis can achieve an SVR12 of 97% and an SVR24 of 95%. Then, these patients can be treated with grazoprevir-elbasvir for 8 weeks.
Keyphrases
- hepatitis c virus
- hepatitis c virus infection
- human immunodeficiency virus
- open label
- end stage renal disease
- newly diagnosed
- clinical trial
- early onset
- peritoneal dialysis
- squamous cell carcinoma
- prognostic factors
- randomized controlled trial
- study protocol
- combination therapy
- smoking cessation
- replacement therapy